Home Treatment of Patients with Low-Risk Pulmonary Embolism with the Oral Factor Xa Inhibitor Rivaroxaban: Prospective Management Trial HoT-PE
Phase of Trial: Phase IV
Latest Information Update: 23 May 2019
Price : $35 *
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Acronyms HoT-PE
- 23 May 2019 Status changed from recruiting to discontinued according to results published in the European Heart Journal.
- 23 May 2019 Interim results (n=525) published in the European Heart Journal.
- 23 Jan 2019 This trial is temporary halted in Germany.